Scarica l'app Stockscreener
19.68
1.60%
-0.32
Dopo l'orario di chiusura:
19.68
Precedente Chiudi:
$20.00
Aprire:
$20.01
Volume 24 ore:
563.56K
Relative Volume:
1.15
Capitalizzazione di mercato:
$1.06B
Reddito:
$2.22M
Utile/perdita netta:
$-40.51M
Rapporto P/E:
-15.32
EPS:
-1.2847
Flusso di cassa netto:
$-46.53M
1 W Prestazione:
+17.42%
1M Prestazione:
+26.07%
6M Prestazione:
+135.97%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$18.57
$20.28
Intervallo di 1 settimana:
$16.37
$21.03
Portata 52W:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Nome
Upstream Bio Inc
Settore
Industria
Telefono
781-208-2466
Indirizzo
890 WINTER STREET, SUITE 200, WALTHAM
Confronta UPB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
19.68 | 1.09B | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-05 | Iniziato | JP Morgan | Overweight |
| 2024-11-05 | Iniziato | Piper Sandler | Overweight |
| 2024-11-05 | Iniziato | TD Cowen | Buy |
| 2024-11-05 | Iniziato | William Blair | Outperform |
Upstream Bio Inc Borsa (UPB) Ultime notizie
Does Upstream Bio Inc. offer margin of safetyMarket Risk Report & Capital Efficiency Focused Strategies - khodrobank.com
Upstream Bio Inc. stock outlook for YEAR2025 Momentum Check & High Win Rate Trade Alerts - Newser
Is Upstream Bio Inc. a strong candidate for buy and holdQuarterly Trade Review & Reliable Breakout Stock Forecasts - khodrobank.com
What MACD and RSI say about Upstream Bio Inc.July 2025 Trade Ideas & AI Based Buy and Sell Signals - Newser
Upstream Bio Announces Positive Phase 2 Trial Results - The Globe and Mail
Developing predictive dashboards with Upstream Bio Inc. dataRate Cut & Technical Pattern Recognition Alerts - Newser
Is Upstream Bio Inc. meeting your algorithmic filter criteriaDay Trade & Free Community Consensus Stock Picks - Newser
Is Upstream Bio Inc. stock poised for growthJuly 2025 Decliners & Weekly Top Performers Watchlists - Newser
Is now a turning point for Upstream Bio Inc.Market Volume Report & Entry Point Confirmation Signals - Newser
Upstream Bio shares rise 1.18% premarket after reporting positive top-line results from the Phase 2 VIBrant trial of Verekitug for the treatment of chronic rhinosinusitis with nasal polyps. - AInvest
Is Upstream Bio Inc. forming a bottoming basePortfolio Return Report & Long-Term Safe Investment Ideas - Newser
How to build a dashboard for Upstream Bio Inc. stockShare Buyback & Free Weekly Watchlist of Top Performers - Newser
Statistical indicators supporting Upstream Bio Inc.’s strengthQuarterly Profit Review & Safe Entry Trade Reports - Newser
Technical signs of recovery in Upstream Bio Inc.Weekly Gains Report & Reliable Volume Spike Trade Alerts - Newser
Signal strength of Upstream Bio Inc. stock in tech scannersRecession Risk & Low Drawdown Investment Ideas - Newser
Upstream Bio Reports Positive Top-Line Results from the - GlobeNewswire
Upstream Bio Shares Surge 18.27% on Strong Phase 2 Trial Data for Verekitug - AInvest
Upstream Bio Inc. stock momentum explainedJobs Report & Momentum Based Trading Signals - Newser
Using economic indicators to assess Upstream Bio Inc. potentialTrade Analysis Report & Daily Oversold Bounce Ideas - Newser
Long term hold vs stop loss in Upstream Bio Inc.Market Activity Report & Safe Entry Momentum Tips - Newser
Analyzing Upstream Bio Inc. with risk reward ratio charts2025 Biggest Moves & Daily Stock Trend Watchlist - Newser
Technical Heatmap Flags Upstream Bio Inc. for WatchCPI Data & Safe Entry Zone Tips - beatles.ru
Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds - Benzinga
Using portfolio simulators with Upstream Bio Inc. includedWeekly Stock Report & AI Forecasted Entry/Exit Points - Newser
Upstream Bio’s Phase 2 win could set it up as a potential Dupixent, Tezspire competitor - Endpoints News
Positive Buy Rating for Upstream Bio, Inc. Driven by Promising Clinical Trial Results for Verekitug - TipRanks
How to interpret RSI for Upstream Bio Inc. stock2025 Top Decliners & Weekly Return Optimization Plans - Newser
Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study - Nasdaq
Upstream Bio’s verekitug meets endpoints in Phase 2 rhinosinusitis trial - TipRanks
Upstream Bio Soars 5.08% on Positive Verekitug Trial Results - AInvest
76% Less Surgery Need: Upstream Bio's Nasal Polyp Drug Verekitug Shows Breakthrough Phase 2 Results - Stock Titan
Trend analysis for Upstream Bio Inc. this week2025 Sector Review & Short-Term High Return Strategies - Newser
Detecting support and resistance levels for Upstream Bio Inc.Market Performance Summary & Weekly Breakout Stock Alerts - Newser
Is Upstream Bio Inc. forming a breakout patternInsider Buying & Entry Point Confirmation Signals - khodrobank.com
Using fundamentals and technicals on Upstream Bio Inc.July 2025 Institutional & Verified Short-Term Plans - Newser
Upstream Bio to Host Conference Call and Webcast to Report - GlobeNewswire
Upstream Bio to Report Top-Line Data from Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps - AInvest
First-in-Class TSLP Antibody Results: Upstream Bio's Verekitug Phase 2 Trial in Nasal Polyps Coming - Stock Titan
Is Upstream Bio Inc. stock a hidden gem2025 Retail Activity & Low Drawdown Momentum Ideas - khodrobank.com
Upstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, Verekitug - MSN
Upstream Bio Inc. recovery potential after sell offTrade Entry Summary & Long-Term Safe Return Strategies - Newser
Can Upstream Bio Inc. outperform in the next rally2025 Technical Patterns & Smart Swing Trading Techniques - khodrobank.com
Historical volatility pattern of Upstream Bio Inc. visualizedJuly 2025 Institutional & Verified Swing Trading Watchlist - Newser
Why Upstream Bio Inc. is moving todayWeekly Stock Analysis & Smart Investment Allocation Insights - Newser
When is the best time to exit Upstream Bio Inc.Quarterly Market Summary & Safe Capital Allocation Plans - Newser
Upstream Bio Inc Azioni (UPB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Upstream Bio Inc Azioni (UPB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):